Science news and discoveries from Mass General Brigham
Bench PressBench PressBench PressBench Press
  • Home
  • About Us
  • Research
    • Brain Research
    • Heart
    • Cancer
    • More…

Study Suggests Diabetes Interventions Reduce Cardiovascular Risk Factors Regardless of Genetic Predisposition to Coronary Artery Disease

By mghresearch | Cardiology, Diabetes, Endocrinology, Medicine | 0 comment | 19 December, 2019 | 0

Patients with type 2 diabetes can have a two to three times higher risk of developing coronary artery disease (CAD). If they also have genetic variants linked to an increased risk of developing CAD—the leading cause of death and disability worldwide—the health implications become more dire.

The good news is diseases such as type 2 diabetes and CAD are not influenced solely by genetics, but by a complex interplay of genetic and environmental factors.

Diabetes interventions such as implementing lifestyle changes (increasing exercise, improving diet, etc.) or taking medication can help reduce this risk. But do those strategies work the same for patients who are at a high genetic risk for CAD as well?

Researchers from the Center for Genomic Medicine and the Diabetes Unit at Massachusetts General Hospital recently took a closer look at this question with the help of data provided by participants in the Diabetes Prevention Program (DPP).

Jordi Merino, PhD

The team, which was led by Jordi Merino, PhD, and Jose Florez, MD, PhD, recently published their findings in the journal Diabetes. Dr. Florez is chief of the Diabetes Unit and an MGH Research Scholar 2013-2018.

Details of the Study

The study team started by building a polygenic risk score for coronary artery disease based on 201 known gene variants that have associated with an increased risk of CAD.

In a study of more than 2,650 DPP participants with dysglycemia, the team measured the effects of the polygenic risk score on cardiometabolic risk factors, and the extent to which diabetes prevention strategies, including lifestyle interventions or regularly taking the diabetes drug metformin, interacted with genetic liability over the course of a year.

The cardiometabolic risk factors assessed in the study included:

  • Body mass index (BMI)
  • Waist circumference
  • Fasting glucose
  • Blood pressure
  • Lipid levels including total cholesterol, LDLc, HDLc, and triglycerides
  • Inflammatory and thrombolytic markers including c-reactive protein, fibrinogen, and tissue plasminogen activator

What They Found

Jose Florez, MD, PhD

The team found that the genetic risk score is associated with several cardiometabolic risk factors at baseline.

Participants in both intervention groups demonstrated greater risk reduction compared to those in the placebo group—and these improvements occurred irrespective of an individual’s genetic risk for coronary artery disease.

Participants in the lifestyle intervention group improved the most across all risk factors in comparison to the placebo group. Not surprisingly, they also had the greatest changes in physical activity, diet and body shape.

Individuals in the metformin group showed significant improvement in BMI, waist circumference and levels of cholesterol, tissue plasminogen activator and c-reactive protein.

Those in the metformin group who also incorporated healthy lifestyle behaviors received additional benefits in terms of reduced risk, which suggests a combined approach could be even more effective.

Limitations of the Study

The team cautions that their findings are based on a unique randomized clinical trial that made replication of reported findings challenging.

They also assigned risk factors to participants based on a composite genetic risk score, and there may be other undiscovered genetic variants related to CAD that could show different results.

Next Steps

The team will next try to find a way to replicate these findings, which will be challenging considering the unique study set.

They will also take a closer look at individual lifestyle interventions to see which ones are most effective when combined with metformin treatment.

About the Mass General Research Institute
Research at Massachusetts General Hospital is interwoven through more than 30 different departments, centers and institutes. Our research includes fundamental, lab-based science; clinical trials to test new drugs, devices and diagnostic tools; and community and population-based research to improve health outcomes across populations and eliminate disparities in care.
Support our Research

No tags.

Related Post

  • To Mars and Beyond: Exploring Innovative Solutions to the Challenges of Space Travel

    By mghresearch | 1 comment

    If you could only bring two shoeboxes worth of medical supplies—from first aid kits to surgical tools— with you on a three-year space mission, what would you bring?

  • Antibiotic pills

    Are You Actually Allergic to Penicillin? Researchers Find New Methods to Confirm Antibiotic Allergies

    By mghresearch | 0 comment

    Mass General researchers are working to increase the safe use of penicillins in patients who have a recorded penicillin allergy but are not actually allergic.

  • Re-Thinking Mental Health Treatment: World Health Day 2017

    By mghresearch | 0 comment

    Did you know that more than 300 million people worldwide live with depression? That number has increased 18% between 2005 and 2015, according to the World Health Organization (WHO). With such staggering numbers, it’s no surprise that WHO has chosen depression as its theme for this year’s World Health Day, which is celebrated today, April 7th.

  • New Study Finds Low-Dose Aspirin May Lower Risk of Cancer Death

    By mghresearch | 1 comment

    A new study from Massachusetts General Hospital reports that long-term regular aspirin was associated with a lower risk of dying from various types of cancers.

  • Mass General Stands Up for Science

    By mghresearch | 0 comment

    The Boston March for Science will celebrate the discovery, understanding and sharing of scientific knowledge. Several groups from Massachusetts General Hospital are working together to organize and ensure a strong presence to reaffirm the message about the essential role that science – biomedical research, in particular – plays in improving life and health.

  • Adhering to Treatment During Adolescence Keeps HIV-Positive Youth on a Healthier Track

    By mghresearch | 0 comment

    Individuals born with HIV are more likely to have difficulty managing their treatment as teens and young adults than they did as children.

  • Celebrating the Role of Women in Science and Much More

    By mghresearch | 2 comments

    Interested in the newest research studies and hot topics? Check out the latest issues of “From the Lab Bench”, a monthly newsletter from the Office of the Scientific Director at the Mass General Research Institute, and “Research Roundup”, our monthly recap of the latest biomedical research news.

  • Research Rumble Recap and the Art of Effective Science Communication

    By mghresearch | 1 comment

    Last night five researchers from Massachusetts General Hospital and Brigham and Women’s Hospital showed off their science communication skills in a Research Rumble at the Cambridge Public Library as part of Cambridge Science Festival. Co-DirectorRead more

Leave a Comment

Cancel reply

Your email address will not be published. Required fields are marked *

  • About
  • About Us
  • Brain Research
  • Cancer
  • Communicating Science
  • Contenido en español
  • COVID-19
  • Events
  • Heart
  • History
  • Home (OLD)
    • Disclaimer
    • Home
  • Just kidding!
  • MGH Chief Academic Officer Job Description
  • MGRI Image Awards
  • MGRI Image Awards
  • MGRI Science Communications Intern
  • Research
  • Research News Funding Opportunities
  • Research News: Announcements & Events
  • Science Slam Tips and Tricks
  • Subscribe
Bench Press